⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 25, 2026Kidney International ReportsOpen Access

WCN26-4831 Association between Corticosteroid Therapy and Adverse Events in Patients with IgA Nephropathy: A Post Hoc Analysis of Two Nationwide Japanese Cohort Studies

Kento Kitamura Masahiro Okabe Takaya Sasaki Akihiro Shimizu Kentaro Koike Hiroyuki Ueda Nobuo Tsuboi Tetsuya Kawamura Yusuke Suzuki Takashi Yokoo

View Full Paper

Ask AI

Bookmark

Share

Key Points

To investigate the relationship between corticosteroid therapy and adverse events in patients with IgA nephropathy.
Post hoc analysis of two nationwide cohort studies
Assessment of corticosteroid therapy outcomes
Evaluation of adverse events related to treatment
Corticosteroid therapy was linked to higher rates of adverse events
Variation in outcomes based on treatment duration
Potential for reconsideration of therapy pathways for IgA nephropathy

Implication

Post hoc analysis shows corticosteroid therapy affects adverse events in patients with IgA nephropathy, suggesting clinical implications.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kitamura et al. (2026) studied this question.

synapsesocial.com/papers/69c770888bbfbc51511e0a67 https://doi.org/10.1016/j.ekir.2026.104796

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Targeting the Alternative Complement Pathway by Iptacopan Abrogates C3 and Strongly Reduces C5b-9 Deposition within Glomeruli in IgA Nephropathy Recurrence after Kidney Transplantation2025 · 4 citations
2WCN26-3819 UPDATE TO THE LONG-TERM EFFICACY AND SAFETY OF IPTACOPAN IN C3 GLOMERULOPATHY: 39-MONTH PHASE 2 EXTENSION STUDY DATAEarly-Phase Clinical Trial · 2026
3#2187 Rare disease, novel approach: C3GN and Iptacopan case report2024 · 1 citations
4WCN26-5007 STEROID TOXICITY IN CHILDREN WITH IgA NEPHROPATHY: WAS IT WORTH THE WEIGHT?Original Research · 2026
5#277 Update to the long-term safety and efficacy of iptacopan in C3G: 33-month extension study data from patients enrolled in a phase 2 study2024 · 2 citations